[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100643973":3},{"organization":4,"armGroups":7,"interventions":26,"overallOfficials":10,"centralContacts":10,"locations":10,"responsibleParty":31,"collaborators":10,"id":33,"slug":10,"hasResults":34,"nctId":35,"briefTitle":36,"officialTitle":37,"acronym":38,"eligibilityCriteria":39,"healthyVolunteers":40,"sex":41,"minAge":42,"maxAge":43,"enrollmentInfo":44,"targetDuration":10,"studyType":47,"phases":10,"briefSummary":48,"conditions":49,"keywords":10,"overallStatus":55,"whyStopped":10,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":10},{"fullName":5,"class":6},"Medicines360","OTHER",[8,14,18,22],{"label":9,"type":10,"description":11,"interventionNames":12},"Blood Based Biomarkers, Derivation Cohort",null,"To support the identification of cut-offs for risk stratification for conditions such as preeclampsia, fetal growth restriction and gestational diabetes at different timepoints in gestation, in blood-based biomarker products currently in development.",[13],"Other: None (this is an observational study with no intervention)",{"label":15,"type":10,"description":16,"interventionNames":17},"Blood Based Biomarkers, Validation Cohort","To perform clinical validation of blood-based biomarkers using cut-offs at different timepoints in gestation, as defined above for identification of pregnancies at increased risk.",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Retinal Imaging, Development of Algorithm","To develop a retinal imaging algorithm for risk prediction for preeclampsia.",[13],{"label":23,"type":10,"description":24,"interventionNames":25},"Retinal Imaging, Validation of Algorithm","To validate the accuracy and test parameters of retinal imaging for risk prediction and management of pregnancies at risk for preeclampsia.",[13],[27],{"type":6,"name":28,"description":29,"armGroupLabels":30,"otherNames":10},"None (this is an observational study with no intervention)","This is an observational study evaluating biomarkers from blood and ocular imaging for prediction of pregnancy complications and associated risks \\[i.e., preeclampsia (PE), fetal growth restriction (FGR), and gestational diabetes (GDM)\\].",[9,15,19,23],{"type":32,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100643973",false,"NCT07669935","Advancing Stillbirth Prevention Through Innovative Risk Evaluation (ASPIRE) Clinical Study","A Multi-Site, Prospective, Two-Part Longitudinal, Observational Cohort Study Of Pregnant Women To Evaluate Biomarkers For Prediction Of Pregnancy Complications","ASPIRE","Inclusion Criteria:\n\n* Age ≥18 years\n* Nulliparous (no previous births ≥20wk GA)\n* Single viable fetus at the dating ultrasound scan with an ultrasound estimated gestational age of 10 0\u002F7-17 6\u002F7 weeks of gestation\n* Ability to consent and comply with study procedures and follow-up\n\nExclusion Criteria:\n\n* Multiple gestation\n* Inability to provide blood\n* Known fetal chromosomal abnormalities or structural Anomaly (a structural or functional defect with the following three characteristics: 1) of prenatal origin; 2) present at the time of live birth or fetal demise, or in utero; 3) affecting (or has the propensity to affect) the health, survival, or physical or cognitive functioning of the individual\n* Known or anticipated inability to complete study follow-up through delivery at the study site (e.g., planned relocation, transfer of obstetric care to a non-participating institution, or other circumstances making delivery outcome data unavailable)\n* Current or recent (within two months) participation in an interventional clinical study.",true,"FEMALE","18 Years","99 Years",{"count":45,"type":46},5500,"ESTIMATED","OBSERVATIONAL","ASPIRE will be a multi-site, prospective, two-part longitudinal, noninterventional observational cohort study of nulliparous singleton pregnant women to evaluate biomarkers from blood and ocular imaging for prediction of pregnancy complications \\[i.e., preeclampsia (PE), fetal growth restriction (FGR), and gestational diabetes (GDM)\\] and risk of adverse outcomes.",[50,51,52,53,54],"GDM","Preterm Preeclampsia","Preeclampsia","Fetal Growth Restriction (FGR)","Pregnancy Complications","NOT_YET_RECRUITING","2026-06-25",{"date":58,"type":59},"2026-06-29","ACTUAL",{"date":61,"type":46},"2026-07-30",{"date":63,"type":46},"2028-12-01",{"name":5,"class":6}]